Novartis Dubai Figure 03 - Key Opinions in Medicine
Clinical response after guselkumab treatment among adalimumab PASI 90 nonresponders: Results from the VOYAGE 1 and 2 trials | Semantic Scholar
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial - Journal of the American Academy of Dermatology
Figure 3 | Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis | SpringerLink
PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal
Psoriasis Patients With PASI 90 Response Achieve Greater HealthRelate - pdf download
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect
Percentage of PASI 75, PASI 90, PASI 100 and PGA responders at weeks 12... | Download Scientific Diagram
Estimated relationships for PaSI90, PaSI100, and sPGa0/1 responses at... | Download Scientific Diagram
Efficacy Data: VOYAGE 1 Clinical Study | TREMFYA® (guselkumab) | HCP
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture
View of Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study | Acta Dermato-Venereologica
Proportion of patients achieving PASI 75, PASI 90, and PASI 100... | Download Scientific Diagram
Open-label Extension Data: Moderate to Severe Plaque Psoriasis | TREMFYA® (guselkumab) HCP
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
Clearance | UCB
Plaque Psoriasis Skin Clearance | COSENTYX® (secukinumab)
PASI 75, PASI 90, and PASI 100 response by baseline psoriasis severity... | Download Scientific Diagram
Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study | Chinese Medical Journal
PASI-75 and PASI-90 responder rates at weeks 4, 12, 24, and 52.... | Download Scientific Diagram
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
New Novartis data shows Cosentyx™ is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients | Novartis
Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial - Rosmarin - 2021 - Skin Health and Disease - Wiley Online Library
